RT Book, Section
A1 Villano, Janna H.
A2 Olson, Kent R.
A2 Anderson, Ilene B.
A2 Benowitz, Neal L.
A2 Blanc, Paul D.
A2 Clark, Richard F.
A2 Kearney, Thomas E.
A2 Kim-Katz, Susan Y.
A2 Wu, Alan H. B.
SR Print(0)
ID 1179991543
T1 HEPARINS
T2 Poisoning & Drug Overdose, 7e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071839792
LK accessmedicine.mhmedical.com/content.aspx?aid=1179991543
RD 2024/04/23
AB Heparins  (Table  II–32)  have  been  used  for  many  years  as  injectable  anticoagulants  for  prophylaxis  of  thromboembolic  disease  and  management  of  multiple  conditions  including  hypercoagulable  disorders,  venous  thromboembolic  disease,  acute  coronary  syndrome,  and  to  maintain  patency  in  intravascular  access  and  hemodialysis  machines.  Conventional  or  unfractionated  heparin  (UFH)  is  primarily  administered  in  health  care  settings  and  thus  intentional  overdoses  are  rare;  most  cases  involve  inadvertent  iatrogenic  administration  errors.  Low–molecular-weight-heparins  (LMWHs)  are  obtained  from  UFH  and  have  greater  bioavailability,  longer  half-life,  predictable  anticoagulation  with  a  fixed-dose  schedule,  and  are  more  easily  self-administered  by  patients  in  outpatient  settings.